Project Grant R01EY039313
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $498K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- The National Eye Institute awarded Oregon Health & Science University $237,341 on August 1, 2026, to develop curvature and color correction techniques for ultrawidefield optical coherence tomography imaging of the retina under the Vision Research program (CFDA 93.867). The project addresses fundamental limitations in current OCT technology by applying GPU-accelerated ray tracing for geometric reconstruction of the retina to eliminate distortion and curvature artifacts in widefield imaging,...
- The National Eye Institute awarded Oregon Health & Science University $860,190 on February 6, 2026, to develop and test hypoimmune retinal pigment epithelial (RPE) cell transplants designed to survive, engraft, and evade immune rejection in nonhuman primates as a model for treating advanced dry age-related macular degeneration (AMD). The project addresses a critical gap in AMD treatment. Current RPE cell transplant therapies in animal models and early clinical trials require chronic...
- The National Eye Institute awarded Perzeption Inc. $305,406 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and evaluate an efficient photostress recovery assessment method for age-related macular degeneration. The project addresses the need for sensitive functional biomarkers to detect early-stage AMD and measure disease progression or treatment response. Perzeption will develop a novel, personalized, adaptive testing method to assess photostress recovery in...
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $733,137 to the University of California, Los Angeles on September 15, 2025, under the Vision Research program (CFDA 93.867) to explore how genetic variation influences disease progression and therapeutic response in age-related macular degeneration. The project integrates advanced optical coherence tomography imaging with machine learning and artificial intelligence to classify...
- The National Eye Institute awarded $753,787 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop low-cost ultra-widefield retinal optical coherence tomography (OCT) technology based on photonic-electronic integration. The project addresses cost barriers that limit clinical availability of OCT instrumentation used to detect and monitor diabetic retinopathy, age-related macular...
- The National Eye Institute awarded the University of Rochester a $2,215,463 cooperative agreement on March 17, 2026, under the Vision Research program (CFDA 93.867) to develop small molecule PROTAC compounds targeting secretory phospholipase A2-IIA (SPLA2-IIA) for treatment of age-related macular degeneration and related macular dystrophies. The award funds development of proteolysis-targeting chimera compounds designed to induce degradation of SPLA2-IIA, a pro-inflammatory enzyme identified...
- The National Eye Institute awarded The Schepens Eye Research Institute Inc. $506,030 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop an open-source solution for exporting and integrating optical coherence tomography data across institutions. The project addresses a critical barrier in ophthalmic research: OCT imaging data from multiple manufacturers is stored in over ten proprietary, undocumented formats with export tools that are prohibitively slow—exporting a...
- The National Eye Institute of the Department of Health and Human Services awarded $571,206 to the University of Maryland, Baltimore on May 1, 2026, under the Vision Research program (CFDA 93.867) to develop, refine, and validate sensitive and robust adaptive optics-optical coherence tomography (AO-OCT) biomarkers for glaucoma detection and progression monitoring. The project addresses the need for earlier detection of glaucoma progression and mechanistically relevant biomarkers to support...
- The National Eye Institute awarded Massachusetts Eye and Ear Infirmary $663,406 on April 1, 2026, under the Vision Research program (CFDA 93.867) to elucidate the molecular mechanisms of secondary cone degeneration in models of retinitis pigmentosa. The recipient will develop a novel AAV-based retinoic acid signaling activator and test whether it can improve photopic visual acuity in multiple mouse models of retinitis pigmentosa. The work will also aim to elucidate the molecular and cellular...
- The National Eye Institute awarded Oregon Health & Science University $264,435 on May 1, 2026, under the Vision Research program (CFDA 93.867) to define the pathophysiology of microcephaly and chorioretinopathy (MCCRP) associated with defects in the gamma-tubulin ring complex. The project will use conditional knockout mouse models and tamoxifen-inducible endothelial cell-specific Cre recombinase to test the hypothesis that tubgcp4 and tubgcp6 serve critical roles in retinal and brain...